Table 3. Selected Current Clinical Trials of Immunotherapy for Early Stage Lung Cancer.

Study	Drug	Trial Phase	Treatment Arm(s)	Enrollment (actual or planned)	Primary Endpoint
NCT03833154 (PACIFIC-4)	Durvalumab	3	SBRT +/- adjuvant Durvalumab	706	PFS
NCT03110978 (I-SABR)	Nivolumab	2	SBRT +/- adjuvant Nivolumab	140	EFS
NCT03924869 (KEYNOTE-867)	Pembrolizumab	3	SBRT +/- concurrent and adjuvant Pembrolizumab	530	OS and EFS

SBRT, stereotactic body radiation therapy; PFS, progression-free survival; EFS, event-free survival; OS, overall survival.